Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Samuel Raimundo Fernandes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Propensity Score, Drug Monitoring. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Few patients can reach transmural remission in Crohn’s disease (CD) with currently available therapies. Proactive optimization of infliximab (IFX) based on trough levels may potentially improve these results.
Methods
Retrospective cohort study including consecutive CD patients starting treatment with IFX. Rates of transmural remission were compared between patients with and without therapeutic drug monitoring (target level: 5-7 µg/mL). A propensity score–matched analysis was performed to adjust for potential confounders.
Results
A total of 195 CD patients were included, 57.9% receiving proactive therapeutic drug monitoring. The rates of transmural remission were higher in patients under proactive therapeutic drug monitoring (37.2% vs 18.3%; P = .004) with similar results in the propensity score–matched analysis (34.2% vs 17.1%; P = .025). In multivariate analysis, proactive therapeutic drug monitoring was independently associated with transmural remission (odds ratio, 2.95; 95% confidence interval, 1.44-6.06; P = .003).
Conclusions
Proactive optimization of IFX based on trough levels increases the rates of transmural remission in CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal.
- Clínica Universitária de Gastrenterologia da Faculdade de Medicina de Lisboa, Lisbon, Portugal.
- Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii, Porto, Portugal.
- CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal.
ORCID-Profile: Samuel Raimundo Fernandes, Helena Cortez-Pinto, Fernando Magro
Zitieren
APA
Fernandes, S. R., Bernardo, S., Saraiva, S., Rita Gonçalves, A., Moura Santos, P., Valente, A., Araújo Correia, L., Cortez-Pinto, H., & Magro, F. (2024). Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad272
Vancouver
Fernandes SR, Bernardo S, Saraiva S, Rita Gonçalves A, Moura Santos P, Valente A, et al. Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad272
BibTeX
@article{Fernandes2024,
author = {Fernandes, Samuel Raimundo and Bernardo, Sónia and Saraiva, Sofia and Rita Gonçalves, Ana and Moura Santos, Paula and Valente, Ana and Araújo Correia, Luís and Cortez-Pinto, Helena and Magro, Fernando},
title = {Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad272}
}
EUVIMED